Patents by Inventor Marijn Van Der Neut Kolfschoten

Marijn Van Der Neut Kolfschoten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for heterologous repRNA immunizations
    Patent number: 11964007
    Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: April 23, 2024
    Assignees: Janssen Vaccines & Prevention B.V., Massachusetts Institute of Technology
    Inventors: Ronald Vogels, Marijn Van Der Neut Kolfschoten, Darrell J. Irvine, Ron Weiss, Ely Blanton Porter, Mariane Bandeira Melo, Tasuku Kitada
  • Methods and Compositions for Heterologous repRNA Immunizations
    Publication number: 20220111033
    Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Ronald Vogels, Marijn Van Der Neut Kolfschoten, Darrell Irvine, Ron Weiss, Ely Porter, Mariane Bandeira Melo, Tasuku Kitada
  • Methods and compositions for heterologous repRNA immunizations
    Patent number: 11235051
    Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: February 1, 2022
    Assignees: Janssen Vaccines & Prevention B.V., Massachusetts Institute of Technology
    Inventors: Ronald Vogels, Marijn Van Der Neut Kolfschoten, Darrell J. Irvine, Ron Weiss, Ely Blanton Porter, Mariane Bandeira Melo, Tasuku Kitada
  • RNA Replicon Encoding a Stabilized Corona Virus Spike Protein
    Publication number: 20210347828
    Abstract: RNA replicons encoding stabilized recombinant pre-fusion SARS CoV-2 S proteins are described. Also described are pharmaceutical compositions and uses of the RNA replicons.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 11, 2021
    Inventors: Jason DEHART, Christian MAINE, Brett Steven MARRO, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Jaroslaw JURASZEK, Aneesh VIJAYAN
  • SARS-CoV-2 Vaccines
    Publication number: 20210346492
    Abstract: RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 11, 2021
    Inventors: Jason DEHART, Christian MAINE, Brett Steven MARRO, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Aneesh VIJAYAN
  • STABLE IgG4 ANTIBODIES
    Publication number: 20210061919
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Application
    Filed: July 15, 2020
    Publication date: March 4, 2021
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Tom VINK, Janine SCHUURMAN, Paul PARREN, Rob AALBERSE, Marijn VAN DER NEUT KOLFSCHOTEN
  • Stable IgG4 antibodies
    Patent number: 10752695
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Genmab A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • METHODS AND COMPOSITIONS FOR HETEROLOGOUS REPRNA IMMUNIZATIONS
    Publication number: 20200230225
    Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Inventors: Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Darrell J. IRVINE, Ron WEISS, Ely Blanton PORTER, Mariane Bandeira MELO, Tasuku KITADA
  • STABLE IgG4 ANTIBODIES
    Publication number: 20170029521
    Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Application
    Filed: June 29, 2016
    Publication date: February 2, 2017
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Tom VINK, Janine SCHUURMAN, Paul PARREN, Rob AALBERSE, Marijn VAN DER NEUT KOLFSCHOTEN
  • Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
    Patent number: 9512201
    Abstract: The disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to Hepatitis B viruses, and have a broad neutralizing activity against such Hepatitis B viruses. The disclosure further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of Hepatitis B.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: December 6, 2016
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Ingrid van den Nieuwenhof, Marijn van der Neut Kolfschoten, Constantin Adrian Apetri, Robert H. E. Friesen
  • HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING HEPATITIS B VIRUSES AND USES THEREOF
    Publication number: 20150232537
    Abstract: The disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to Hepatitis B viruses, and have a broad neutralizing activity against such Hepatitis B viruses. The disclosure further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of Hepatitis B.
    Type: Application
    Filed: September 24, 2013
    Publication date: August 20, 2015
    Inventors: Ingrid van den Nieuwenhof, Marijn van der Neut Kolfschoten, Constantin Adrian Apetri, Robert H.E. Friesen
  • STABLE IGG4 ANTIBODIES
    Publication number: 20130345406
    Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Applicant: GENMAB A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten